Regulation of hepatic gene expression by saturated fatty acids  by Vallim, T. & Salter, A.M.
ARTICLE IN PRESS
Prostaglandins, Leukotrienes and Essential Fatty Acids 82 (2010) 211–218Contents lists available at ScienceDirectProstaglandins, Leukotrienes and
Essential Fatty Acids0952-32
doi:10.1
n Corr
E-m
1 Cu
School
90095,journal homepage: www.elsevier.com/locate/plefaRegulation of hepatic gene expression by saturated fatty acidsT. Vallim 1, A.M. Salter n
Division of Nutritional Biochemistry, School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, Leicester LE12 5RD, UKa b s t r a c t
Diets rich in saturated fatty acids have long been a
concentrations and hence increased risk of cardiovascul
suggested to promote the development of non-alcoh
considerable evidence to suggest that polyunsaturated
regulating the activity of transcription factors, includin
sterol regulatory binding proteins (SREBPs) and liver X
fatty acids act is still limited. Here we review the poten
modulate hepatic lipid metabolism thereby impacting o
Evidence is presented that their effects are, at least partl
of the SREBP family of transcription factors.
& 20178& 2010 Elsevier Ltd.
016/j.plefa.2010.02.016
esponding author. Tel.: +44 115 9516120.
ail address: andrew.salter@nottingham.ac.uk
rrent address: Departments of Biological C
of Medicine at UCLA, 675 Charles E Young D
USA.
Open access under CC BYssociated with increased plasma cholesterol
ar disease. More recently, they have also been
olic fatty liver disease. While there is now
fatty acids exert many of their effects through
g peroxisome proliferator activated receptors,
receptor, our understanding of how saturated
tial mechanisms whereby saturated fatty acids
n the synthesis, storage and secretion of lipids.
y, mediated through modulation of the activity
0 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
It has now been well established that, through a variety of
pathways, including peroxisome proliferator activated receptors
(PPARs), sterol regulatory element binding proteins (SREBPs) and
liver X receptors (LXRs), fatty acids can regulate the expression of
a range of genes involved in lipid and lipoprotein metabolism
within the liver [1–3]. However, much of the existing evidence
relates speciﬁcally to the role of polyunsaturated fatty acids in
regulating gene expression with much less understanding of the
potential roles of saturated fatty acids. In this review, we will
explore the impact of dietary saturated fatty acids on hepatic
metabolism in the development of pathologies such as raised
plasma cholesterol, metabolic syndrome (Met Syn) and non-
alcoholic fatty liver disease (NAFLD) and existing evidence for
direct effects on gene expression.2. Role of the liver in regulating plasma lipoprotein
concentrations
The liver plays a major role in regulating the availability of
lipid to the other tissues of the body by modulating lipid synthesis
and the uptake and secretion of lipoproteins [4,5]. It is a major site
of synthesis of both cholesterol and triacylglycerol. A reciprocal(A.M. Salter).
hemistry and David Geffen
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-NC-ND license. relationship between dietary cholesterol intake and hepatic
cholesterol synthesis ensures relatively modest changes in whole
body cholesterol concentrations over a fairly wide range of dietary
intakes [6]. Levels of hepatic cholesterol synthesis are very tightly
regulated by a series of intricate negative feedback loops, all of
which serve to keep overall body cholesterol levels very stable. In
addition to distributing such cholesterol around the body through
its secretion within very low density lipoprotein (VLDL), the liver
represents the major site of cholesterol metabolism and excretion
through its conversion to bile acids and subsequent loss in
the faeces. The synthesis of triacylglycerol is largely regulated by
the availability of fatty acids. These can arise from three
major sources; de novo synthesis, diet and release from adipose
tissue [6].
In terms of lipoprotein metabolism, the liver is the site of
assembly and secretion of VLDL and the major site of removal of
chylomicron remnants, intermediate density lipoprotein (IDL) and
low density lipoprotein (LDL) from the circulation. It synthesizes
and secretes apolipoprotein (apo) A1, the major protein compo-
nent of HDL, and actively removes cholesterol from the circulating
HDL particles following interaction with cell surface receptors [7].
When lipid supply exceeds the ability to mobilize lipid the liver
has the capacity to store relatively large amounts of both
cholesterol ester and triacylglycerol.
The synthesis and secretion of VLDL from the liver is largely
governed by lipid substrate supply [6]. The expression of apoB100
appears to be largely constitutive. When sufﬁcient triacylglycerol
is available the apoB is lipidated and a VLDL particle is formed. In
the absence of sufﬁcient triacylglycerol the emerging apoB is
degraded. Transfer of triacylglycerol onto apoB is mediated by the
microsomal triglyceride transfer protein (MTP) [8]. Evidence is
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impaired functioning, reduced VLDL production and associated
accumulation of lipid in the liver [9]. The synthesis of VLDL
certainly appears more complex than originally proposed, and
new genes (e.g. Cideb) have recently been found to play a role in
the addition of triacylglycerol to the developing lipoprotein [10].
While there is evidence to suggest that cholesterol availability
regulates the synthesis and secretion of VLDL, the mechanisms
whereby free and esteriﬁed cholesterol are incorporated into the
particle remain to be fully elucidated.
Cholesterol enters the liver from a variety of sources including
chylomicron remnants, IDL, LDL and HDL. Chylomicron remnants
can be taken up by the LDL receptor related protein and the LDL
receptor [11]. IDL and LDL are taken up by the LDL receptor [10]
and removal of cholesterol from HDL appears to be largely
mediated by interaction with the Scavenger receptor 1B [12]. This
uptake is regulated by intracellular cholesterol concentrations.
Hepatic cholesterol concentration appears to be primarily regu-
lated through a combination of modulation of LDL receptor
expression and de novo synthesis. Over the last 30 years, the
seminal work of Goldstein, Brown and co-workers have eluci-
dated the mechanism whereby the transcription factor, SREBP2,
regulates expression of the genes for many of the enzymes of the
cholesterol synthesis pathway and the LDL receptor (see below),
demonstrating one of the ﬁrst examples of nutrient regulation of
gene expression [13,14].3. Dietary fatty acids and plasma cholesterol
For over 50 years it has been recognized that the amount and
type of fatty acids in the diet have a major impact on plasma
cholesterol concentrations and associated risk of developing
atherosclerotic vascular disease [15]. Epidemiological observa-
tions, such as the 7 countries study, clearly showed that
populations with high dietary intakes of saturated fatty acids
had higher plasma cholesterol levels and an increased incidence
of cardiovascular disease [16]. This was supported human feeding
trials which directly demonstrated that increasing saturated fatty
acid intake increases total plasma cholesterol concentration in a
dose-dependent manner [17,18]. Such ﬁndings have underpinned
dietary advice for reducing cardiovascular risk for several decades.
The development of techniques to separate individual lipo-
protein fractions led to the understanding that cardiovascular risk
not only relates to total plasma cholesterol concentration but also
to the relative proportion of cholesterol carried in individual
lipoprotein fractions. Thus, while a positive relationship exists
between LDL cholesterol and CVD risk, HDL cholesterol has an
inverse relationship and is hence viewed as protective. The major
impact of saturated fatty acids has been shown to be in increasing
LDL cholesterol partially offset by a lesser effects on HDL
cholesterol [19,20]. It has also been recognized that the speciﬁc
structure of fatty acids inﬂuences their impact on lipoprotein
concentration. For example, the cholesterol raising effects of
saturated fatty acids appears to be restricted to those with
between 12 and 16 carbon atoms.4. Dietary fatty acids and non-alcoholic fatty liver disease
(NAFLD)
NAFLD is a term used to describe the accumulation of lipid
within the liver (steatosis) in the absence of signiﬁcant alcohol
intake, which cannot be attributed to viral, congenital or
autoimmune factors [21–23]. It is now widely regarded as the
most common form of chronic liver disease in many WesternCountries and its prevalence appears to be increasing rapidly. This
has been attributed to the ongoing ‘epidemic’ of obesity and
associated insulin resistance, Met Syn and type 2 diabetes.
Estimates of prevalence of NAFLD in the developed countries
suggest that in excess of 30% of the adult population could be
affected [21,23]. The risk of developing NAFLD increases with the
degree of obesity with a reported incidence of 96% in subjects
undergoing bariatric surgery [24]. There also appears to be a close
association between the degree of insulin resistance and in-
cidence of NAFLD [25].
Hepatic steatosis involves the accumulation of intracytoplas-
mic triacylglycerol within hepatocytes. This may be a result of the
formation of large droplets of macrovasicular fat which displace
other components of the cell, including the nucleus or a
combination of large and small droplets [26]. This accumulation
of lipid is often referred to as the ﬁrst ‘‘hit’’ in a ‘‘two-hit’’ process
that leads to non-alcoholic steatohepatisis (NASH), inﬂammation,
cirrhosis and ultimately liver failure [27]. As such, simple steatosis
is often thought to be relatively benign unless a second ‘‘hit’’
subsequently occurs. The nature of this second event remains to
be established but factors such as oxidative stress and/or
circulating inﬂammatory molecules have been implicated [26,28].
Diet is clearly closely associated with risk of developing
NAFLD. Excessive energy intake results in accumulation of
triacylglycerol in adipose tissue and appears to be central to the
aetiology of the disease [22,23,25,26]. Excessive adiposity is
frequently associated with insulin resistance which in turn leads
to unrestrained lipolysis of adipose tissue triacylglycerol and
inappropriate release of free fatty acids into the circulation. In
many individuals this leads to the cluster of metabolic distur-
bances (high plasma TAG, low HDL cholesterol, hypertension and
glucose intolerance) which make up Met Syn [29].
While dietary fat appears to directly provide a relative small
proportion of the fatty acids incorporated into hepatic triacylgly-
cerol, it does of course represent the primary source of adipose
tissue fatty acids which may be subsequently released and re-
esteriﬁed in the liver [30]. The speciﬁc nature of dietary fatty acids
may also directly impact on hepatic de novo lipogenesis [31]. It
has been reported that dietary fatty acids impact on lipogenesis
by directly regulating the expression of key enzymes involved in
fatty acid synthesis particularly, acetyl coenzyme A carboxylase
(ACC), fatty acid synthase (FAS) and stearoyl CoA desaturase
(SCD1) [31–33]. It is now well established, at least in animal
models that polyunsaturated fatty acids can speciﬁcally down-
regulate expression of the genes for these enzymes [1–3]. By
contrast, it has been suggested that saturated fatty acids may
actually stimulate the expression of these enzymes [31–33].
Evidence for these effects and potential mechanisms are discussed
below.5. Regulation of hepatic gene expression by fatty acids
It is clear that fatty acids have the ability to alter a number of
pathways involved in lipid and lipoprotein metabolism within the
liver. In recent years considerable progress has been made in
understanding mechanisms whereby fatty acids can regulate the
expression of genes for enzymes, apolipoproteins and receptors
involved in lipid metabolism. Much of this has focussed on the
impact of polyunsaturated fatty acids. The ability for polyunsa-
turated fatty acids to down-regulate the expression of genes for
enzymes involved in fatty acid synthesis, including ACC, FAS and
SCD, has been recognized for some time [1–3]. These genes appear
to be repressed by both n-3 and n-6 PUFA though response to the
former may be more profound.
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major role in the fatty acid-induced regulation of hepatic gene
transcription. These include PPARa, LXR, and SREBPs. PPARs and
LXR are members of the nuclear hormone receptor superfamily of
transcription factors. These ligand-activated intracellular tran-
scription factors bind to speciﬁc motifs (response elements)
within the promoters of genes as heterodimers with the retinoid
X receptor (RXR). Ligand binding appears to initiate conforma-
tional changes which displace co-repressors and facilitate inter-
action with co-activators [34]. Through a reorganization of the
chromatin and modiﬁcation or recruitment of a range of factors
involved in gene expression this leads to activation of
transcription.6. Peroxisome proliferator-activated receptor-alpha
PPARs are the most extensively characterised nuclear recep-
tors that are regulated by fatty acids [35]. There are three
isoforms, PPARa, PPARb (also known as d) and PPARg, with PPARa
being the predominant isoform in liver.
Ligand activation of PPARa is associated with transcriptional
up-regulation of a wide range of genes for proteins associated
with fatty acid oxidation and lipoprotein metabolism, these
include; acyl coenzyme A oxidase, carnitine palmitoyl transferase
1, lipoprotein lipase, apolipoproteins AI and CIII [36]. A diverse
range of compounds act as ligands for the various PPAR isoforms.
This includes both saturated and unsaturated fatty acids, though
in general PUFA tend to be more potent. While all three PPAR
subtypes have been shown to bind n-3 and n-6 PUFA [37,38],
afﬁnity appears to be greatest for PPARa followed by PPARg and
PPARb [37]. Furthermore, a range of eicosanoids, derived form n-3
and n-6 PUFA, have also been shown to be PPAR ligands, often
with greater afﬁnity than their parent molecules [37]. Interest-
ingly, an endogenous ligand for PPARa has recently been
described to be a phospholipid with a palmitate and an oleate
moiety. The ability of this phospholipid to activate PPARa seems
to require FAS [39], suggesting cellular rather than dietary-
derived fatty acids may be more important. Furthermore, these
observations suggest the different pools of fat within the cell itself
may be important in determining fatty acid function.Table 1
Effect of over-expression of SREBPs on gene expression.
Target gene SREBP1c SREBP1a SREBP2
LDL receptor 0.9 2.6 5.8
HMGCoA synthase 1.0 3.1 13.0
HMGCoA reductase 1.0 3.9 75.0
Squalene synthase 0.7 3.1 10.0
ACC 2.1 9.4 7.4
FAS 3.9 16.0 15.0
SCD1 3.0 6.8 2.7
Data shows fold change in hepatic mRNA concentration in transgenic mice over-
expressing each of the SREBPs compared to wild-type animals (compiled from
Refs. [60–62]).7. Liver X receptors
LXRs have been described as sensors of cholesterol in the
nucleus as they are activated by increased intracellular cholester-
ol concentrations. The naturally occurring oxysterols 22-R-
hydroxycholesterol and 24, 25-epoxycholesterol and long chain
fatty acids have been identiﬁed as ligands for LXRs [40]. There are
two LXR family members, and LXRa is the most highly expressed
isoform in the liver with LXRb being ubiquitously expressed in
most cell types, but not hepatocytes [41]. As with PPARs, LXRs
bind to response elements as heterodimers with RXR. They
regulate the expression of genes involved in sterol and fatty acid
metabolism, particularly hepatic bile acid synthesis, including
adenosine triphosphate-binding cassette protein A1 (ABCA1,
involved in reverse cholesterol transport), apolipoprotein E,
lipoprotein lipase, cholesterol ester transfer protein, and phos-
pholipid transfer protein [42]. LXRs also play an important role in
the regulation of genes involved in other aspects of metabolism
including lipogenesis [43] and carbohydrate metabolism [44,45].
Recent evidence suggests that the regulation of lipogenesis by LXR
is mediated primarily by its effects on SREBP1c expression (see
below). A link between LXR activation and plasma LDL levels was
also recently unravelled, with the identiﬁcation of a novel LXRtarget gene termed IDOL, an E3 ubiquitin ligase that regulates LDL
receptor at the protein level [46]. PUFA have been reported to
inhibit the interaction of oxysterols with LXR and thereby inhibit
its activation of target genes [47–49].8. Sterol regulatory element binding proteins
SREBPs are membrane-bound members of the basic helix-
loop-helix leucine zipper (bHLHLZ) family of transcription factors.
They play a major role in regulating the expression of genes
associated with lipid and lipoprotein metabolism [50–52]. Two
SREBP genes produce three separate proteins (SREBP1a and 1c
from one and SREBP2 from the other) with SREBP1c and SREBP2
being the predominant isoforms in the liver. Each of the SREBP
proteins is synthesized in an immature form which resides on the
endoplasmic reticulum (ER) and is then activated by a two-step
proteolytic process in the Golgi apparatus [50]. SREBPs are
transported to the Golgi through the action of an escort protein
called SCAP [53]. SCAP contains binding sites for COPII proteins
which cluster the SCAP-SREBP complex into COPII coated vesicles
[54]. These vesicles then bud from the ER and fuse with the Golgi.
Increases in cellular cholesterol cause conformational changes in
SCAP leading to the retention of SREBP in the ER [55] as a result of
binding of SCAP to two ER anchor proteins called Insig 1 and 2
[56]. The binding of Insig to SCAP inhibits its interaction with
COPII proteins and thus retards its movement to the Golgi [53]. In
turn, this leads to reduced proteolysis and a decrease in the
nuclear active form of SREBP. The ER contains surprisingly low
levels of cholesterol [57] and therefore provides an appropriate
location for the regulation of cellular cholesterol levels. Indeed,
SREBP cleavage in the ER was shown to be very responsive to
relatively small changes in ER cholesterol levels [58]. This
sensitivity to changes in intracellular sterol concentrations may
not apply to all three SREBP isoforms. While evidence from
studies using cell lines indicate that both SREBP1a and SREBP2
display such sensitivity to sterols, in vivo studies indicate SREBP1c
may not respond to sterol depletion [59].
The transcriptionally active SREBP translocates to the nucleus
where it binds to sterol regulatory elements (SREs) on target
genes. While there is a sizeable overlap in the speciﬁcities of the
individual SREBP isoforms, studies in transgenic mice over-
expressing truncated nuclear active forms of SREBP in liver have
shown speciﬁc roles for each isoform (Table 1). Over-expression
of SREBP2 results in a vast increase in cholesterol synthesis
through the up-regulation a number of the enzymes of the
cholesterol synthetic pathway [60]. As discussed below SREBP2
always plays a major role in the regulation of expression of the
LDL receptor. Over-expressing the nuclear form of SREBP1a
results in the accumulation of cholesterol and triglycerides in
the liver [61] while over-expressing SREBP1c causes an increase in
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Fig. 1. Impact of dietary fat and cholesterol on (a) plasma lipoprotein cholesterol and (b) liver lipids in the hamster. Animals were fed a diet with (HF) or without (LF) 17.5%
by weight fat formulated to mimic the fatty acid composition of a Western diet, in the absence (LC) or presence (HC) of 0.2% by weight cholesterol, for 4 weeks. Lipoproteins
were separated by preparative ultracentrifugation and lipoprotein and liver lipids determined enzymatically.
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[62]. This suggests that while SREBP2 is predominantly involved
in regulating cholesterol metabolism, SREBP1c primarily regulates
fatty acid synthesis while SREBP1a can regulate enzymes of both
the cholesterol and fatty acid synthetic pathways. However, as
discussed below, there may not be as strict a demarcation of
function of the SREBP isoforms as originally proposed.
PUFA have been shown to decrease nuclear SREBP-1 protein
levels without affecting SREBP2 [63]. Thus, the role of SREBP1c in
regulating lipogenic gene expression makes it an obvious
candidate for mediating the effects of PUFA on lipogenesis. Cell
culture studies have clearly shown that PUFA have the ability to
reduce SREBP1a and 1c mRNA and SREBP-1 protein concentra-
tions [64]. This effect of PUFA on SREBP mRNA concentrations has
been attributed to both repression of gene transcription and
increased turnover of the mRNA. As indicated above, at least part
of this effect may be mediated through LXR. PUFA inhibition of the
interaction of oxysterols with LXR may directly impact its abilityto activate SREBP1c transcription [65–67]. Both the mouse and
the human SREBP1c promoters have been shown to contain
potential LXREs [68]. Thus, inhibition of the association of LXR
with its oxysterol ligands by PUFA may repress activation of
transcription of the SREBP1c gene by LXR. Another potential
mechanism is the inhibition of LXR transcriptional activity by
PUFA activation of PPARs. Over-expression of PPARa and PPARg in
HEK-293 cells has been shown to inhibit SREBP1c promoter
activity and this effect was abolished by mutating the putative
LXREs in the SREBP1c promoter [69]. It has been suggested that
this was a result of increased competition between PPAR and LXR
for association with its transcriptional partner RXR. There is also
data to suggest PUFA may affect the nuclear abundance of SREBP
isoforms by regulating proteasomal degradation of these proteins
[70]. Thus, it appears that the regulation of lipogenic gene
expression by dietary PUFA is a result of a complex interaction
between a number of transcription factors including SREBPs,
PPARs and LXR.
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So far, much of this discussion has focussed on the effects of
PUFA on hepatic gene expression. However, as already discussed,
it is clear that dietary saturated fatty acids have a major impact on
the development of both raised plasma LDL concentrations and
the genesis of NAFLD. Is there evidence that these effects are a
result of modulation of hepatic gene expression by saturated fatty
acids? Using the hamster as a model species, Dietschy and
colleagues [71] clearly demonstrated that saturated fatty acids
with between 12 and 16 carbon atoms reduced receptor mediated
uptake of LDL by the liver. They concluded that reduced hepatic
clearance of LDL (rather than increased production) was the
predominant mechanism whereby such saturated fatty increased
plasma LDL cholesterol concentrations [71,72]. Subsequently, in
the same species we showed that diets enriched in trimyristin or
tripalmitin reduced LDL receptor mRNA concentration in a dose-
dependent manner [73,74]. More recently, we have been
investigating the impact of a diet rich in saturated fat, formulated
to mimic the fatty acid composition of a typical Western diet, on
the expression of a range of genes in the liver (Vallim, Bennett
and Salter, unpublished data). Fig. 1 indicates that, in the absence
of added cholesterol such a diet modestly increases the
concentration of VLDL and LDL cholesterol. When cholesterol is
added to the diet the effect is potentiated. It was also of note
that, in the absence of cholesterol, the high fat diet had little
impact on hepatic lipid concentration. However, when cholesterol
was added there was a modest increase in hepatic TAG
concentration and a dramatic increase in storage of hepatic
cholesterol ester. The lack of effect of the high fat diet (in the
absence of cholesterol) on hepatic lipids is contrary to what is
frequently seen in mice [75]. For example, Oosterveer et al. [31]
fed male C57B1/6J mice a high saturated fat diet, similar to that
used in our study, for a period of 6 weeks. At the end of the study
hepatic TAG was approximately 80% higher than in control mice
(16.4 vs. 9.2 mmol/g) fed a low fat chow. Total hepatic cholesterol
(free+esteriﬁed) also increased but to a lesser extent (9.8 vs.
6.9 mmol/g).
We also examined the effect of dietary fat and cholesterol on
the expression of a number of hepatic genes (Fig. 2). Fat and
cholesterol feeding were both associated with a reduction inSR
SR
AC
FA
SC
LD
Fig. 2. Impact of dietary fat and cholesterol on hepatic mRNA concentrations in the h
SREBP1c and 2, ACC and FAS were determined by quantitative real-time PCR and are n
protein. Data are expressed relative to the mean value for animals on the LC/LF diet. Da
independent variables (p-values for independent or interactive effects are presented).SREBP2 and LDL receptor mRNA concentrations. This is consistent
with the well established role of SREBP2 in regulating LDL
receptor expression through direct interaction with an SRE in
the promoter of the receptor gene and is supported by the strong
correlation seen between SREBP2 and LDL receptor mRNA across
all of the diets (Fig. 3a). Cholesterol feeding and the associated
accumulation of cholesterol in the liver are likely to inhibit the
maturation of SREBP2 at the endoplasmic reticulum, thus limiting
the availability of mature, nuclear SREBP2. As the SREBP2 gene
contains an active SRE and has been shown to auto-regulate its
own transcription this would lead to a reduction in transcription
of the SREBP2 gene and further reduce nuclear SREBP availability.
The mechanism whereby dietary fat is reducing SREBP2 mRNA
remains to be established, but this is again likely to be the cause of
the reduction in LDL receptor expression. It has been suggested
that saturated fatty acids represent a poor substrate for
cholesterol esteriﬁcation [76] and that this may lead to a
redistribution of cholesterol within the cell. This in turn may
lead to a regulation of SREBP2 maturation by free cholesterol or
its oxidized derivatives. The reduced storage of cholesterol in the
liver of animals fed both cholesterol and fat (Fig. 1b) supports this
hypothesis.
The effect of these diets on SREBP1c mRNA was very different
to SREBP2. While dietary cholesterol modestly increased SRBBP1c
mRNA concentrations, dietary fat had no effect. Analysis of the
concentrations of immature and mature SREBP1c suggested that
there was no signiﬁcant difference in expression of maturation
with any of the diets studied (data not shown). Despite the lack of
effect on this regulator of lipogenic gene expression, major effects
were seen in the mRNA concentrations for the potential target
genes: ACC, FAS and SCD1. Both cholesterol and fat reduced ACC
and FAS mRNA concentration but the effect was not additive. By
contrast, while cholesterol on its own had very little effect on
SCD1 expression, dietary fat dramatically reduced SCD1 mRNA.
Adding cholesterol to the diet appeared to markedly attenuate the
effect of fat on SCD1 expression. No signiﬁcant correlation was
seen between SREBP1c mRNA and either ACC mRNA (r=0.255,
p=0.174) or FAS mRNA (Fig. 3b, r=0.182, p=0.336) but there was
with SCD1 mRNA (r=0.508, p=0.004). However, while both ACC
mRNA (r=0.692, po0.001) and FAS mRNA (Fig. 3c, r=0.703,
po0.001) strongly correlated with SREBP2 mRNA, SCD1 mRNAChol Fat Chol x Fat
EBP1c 
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amster. Animals were treated as described in Fig. 1. Concentrations of mRNA for
ormalized to mRNA concentrations for the house-keeping gene TATA box-binding
ta were analysed by 2-way analysis of variance with dietary cholesterol and fat as
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Fig. 3. Correlation of hepatic SREBP mRNA with LDL receptor and fatty acid synthase mRNA. Data represent hepatic mRNA values for individual animals as described in
Fig. 2: (a) SREBP2 mRNA vs. LDRr mRNA, (b) SREBP1c mRNA vs. FAS mRNA and (c) SREBP2 mRNA vs. FAS mRNA.
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must be viewed with caution they do suggest differences in the
regulation of these lipogenic enzymes by SREBP isoforms and that,
in certain situations ACC and FAS could possibly be regulated by
SREBP2 as well as SREBP1c. This is supported by early datalooking at the impact of over-expression of individual SREBP
isoforms on gene expression in the mouse (Table 1). Over-
expression of SREBP2 increased ACC and FAS (but not SCD) mRNA
to a greater extent than SREBP1c [60]. Interaction of SREBP2
(either as a homodimer or heterodimers with SREBP1a or 1c) with
ARTICLE IN PRESS
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expression [77]. Furthermore, increasing SREBP2 expression
in vivo, by severely reducing cholesterol availability in mice, has
been shown to increase FAS expression [78]. This was shown to be
associated with an increased binding of SREBP2 to the FAS gene
promoter.
The effects of the high fat diet on ACC, FAS and SCD expression
in the hamster are very different from those in the mouse. In the
study by Oosterveer et al. [31], mRNA for each of these three
genes, and indeed for SREBP1c, was reported to increase in
response to the high fat diet. Earlier studies by Lin et al. [32] have
suggested that this may be due to an increase in expression of the
SREBP1c activator, PGC-1b, although this was a very short-term
(48 h) feeding study. Interestingly, despite the changes in ACC and
FAS expression, Oosterveer et al. [31] reported that the accumula-
tion of hepatic lipid, in mice fed the high fat diet, was associated
with chain elongation and desaturation rather than de novo fatty
acid synthesis. The reduction in SCD1 expression in hamsters (as
compared to the increase in mice) on the saturated fat-rich diet
(Fig. 2) may explain why in this species we saw no lipid
accumulation.10. Conclusions
High intakes of dietary saturated fatty acids increase plasma
cholesterol, particularly that within the LDL fraction. This appears
to be through down-regulation of hepatic LDL receptor expres-
sion, probably through modulation of activity of SREBP2. The
exact mechanism by which saturated fatty acids regulated SREBP2
activity still remain to be established. The effects of dietary
saturated fat on hepatic steatosis appear to be species dependent.
In the mouse, such diets increase SREBP1c expression and its
downstream targets. Recent evidence suggest that an increase in
elongation and desaturation of fatty acids in the liver produces
increased amounts of oleic acid and may be central to this effect
[31]. By contrast, a diet rich in saturated fat was shown to down-
regulate lipogenic gene expression in the hamster (including
SCD1) which appeared resistant to the effects of such fatty acids
on hepatic lipid accumulation. These experiments also provide
preliminary in vivo evidence that, at least in some circumstances,
the SREBP isoforms may be more promiscuous than generally
believed and that SREBP2 can play a role in regulating lipogenic
gene expression.Conﬂicts of interest
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